If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): Administration of Olanzapine Pamoate
Olanzapine pamoate is for deep intramuscular gluteal injection only. Do not administer intravenously or subcutaneously. For full information on reconstitution and administration please refer to the summary of product characteristics.
Injection
Based on Label Information
Table
1 confirms the final ZypAdhera suspension volume to
inject. Suspension concentration is 150 mg/ml olanzapine.1
Table
1. Confirm the final ZypAdhera suspension volume to inject1
Dose
(mg)
Final
volume to inject (ml)
150
1.0
210
1.4
300
2.0
405
2.7
Suspension
concentration is 150 mg/ml olanzapine.
1.
Determine which needle will be used to administer the injection to
the patient. For obese patients, the 50 mm is recommended for
injection:1
▪ If
the 50 mm needle is to be used for injection, attach the 38 mm safety
needle to the syringe to withdraw the required suspension volume.
▪ If the 38 mm needle is to be used for the
injection, attach the 50 mm safety needle to withdraw the required
suspension volume.
2.
Slowly withdraw the desired amount. Some excess product will remain
in the vial.1
3.
Engage the needle safety device and remove needle from syringe.1
4.
Attach the selected 50 mm or 38 mm safety needle to the syringe prior
to injection. Once the suspension has been removed from the vial, it
should be injected immediately.1
5.
Select and prepare a site for injection in the gluteal area. DO NOT
INJECT INTRAVENOUSLY OR SUBCUTANEOUSLY.1
6.
After insertion of the needle, aspirate for several seconds to ensure
no blood appears. If any blood is drawn into the syringe, discard the
syringe and the dose and begin reconstitution and administration
procedure again.
The injection should be performed with steady,
continuous pressure.1
7.
Engage the needle safety device (Figure
1 - Fig. 1 and 2).1
8.
Discard the vials, syringe, used needles, extra needle and any unused
solvent in accordance with appropriate clinical procedures. The vial
is for single use only.1
1.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Date of Last Review:January 24, 2018
Was this answer helpful to you?
Contact Lilly
Phone
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com